LungLife AI, Inc.
Not enough financial coverage to compute a composite score for LLA.L. This is typical for foreign-listed ADRs, recent IPOs, or thinly-covered small caps. Live quote, chart, and any available data still render below.
Companylunglifeai.com
LungLife AI, Inc. , a diagnostic company, researches and develops clinical diagnostic solutions for lung cancer with artificial intelligence (AI) technology in the United States and the People's Republic of China. The company engages in developing LungLB, a blood-based test to stratify cancerous and benign lung nodules identified by CT scan.
- CEO
- Paul Pagano
- IPO
- 2024
- Employees
- 8
- HQ
- Thousand Oaks, CA, US
Price Chart
Performance & Tape
- 52W High
- $30.00
- 52W Low
- $0.05
- 50D MA
- $1.47
- 200D MA
- $2.01
- Beta
- -0.35
- Avg Volume
- 22.84K
Get TickerSpark's AI analysis on LLA.L
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our LLA.L Coverage
We haven't published any research on LLA.L yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate LLA.L Report →